Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elsa Bernard

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Blood|February 19, 2025
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMTCarmelo Gurnari, Marie Robin, Lionel Adès, et al.
Cancer Cell|April 18, 2026
Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 studyDavid Planchard, Nathalie Cozic, Maria Fernanda Mosele, et al.
Nature Medicine|September 4, 2025
Patritumab deruxtecan in HR<sup>+</sup>HER2<sup>-</sup> advanced breast cancer: a phase 2 trialBarbara Pistilli, Fernanda Mosele, Noemie Corcos, et al.
Blood Cancer Discovery|September 27, 2021
<i>ZBTB33</i> is mutated in clonal hematopoiesis and myelodysplastic syndromes and impacts RNA splicingEllen M Beauchamp, Matthew Leventhal, Elsa Bernard, et al.
The New England Journal of Medicine|April 23, 2025
Tumor-Infiltrating Clonal HematopoiesisOriol Pich, Elsa Bernard, Maria Zagorulya, et al.
Blood|April 30, 2024
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromesMaria Sirenko, Elsa Bernard, Maria Creignou, et al.
Blood|July 3, 2024
Molecular taxonomy of myelodysplastic syndromes and its clinical implicationsElsa Bernard, Robert P Hasserjian, Peter L Greenberg, et al.
Nature Genetics|October 27, 2020
Cancer therapy shapes the fitness landscape of clonal hematopoiesisKelly L Bolton, Ryan N Ptashkin, Teng Gao, et al.
NEJM Evidence|February 6, 2024
Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElsa Bernard, Heinz Tuechler, Peter L Greenberg, et al.
Nature Medicine|May 5, 2021
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Yasuhito Nannya, Robert P Hasserjian, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Blood|February 19, 2025
Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMTCarmelo Gurnari, Marie Robin, Lionel Adès, et al.
Cancer Cell|April 18, 2026
Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 studyDavid Planchard, Nathalie Cozic, Maria Fernanda Mosele, et al.
Nature Medicine|September 4, 2025
Patritumab deruxtecan in HR<sup>+</sup>HER2<sup>-</sup> advanced breast cancer: a phase 2 trialBarbara Pistilli, Fernanda Mosele, Noemie Corcos, et al.
Blood Cancer Discovery|September 27, 2021
<i>ZBTB33</i> is mutated in clonal hematopoiesis and myelodysplastic syndromes and impacts RNA splicingEllen M Beauchamp, Matthew Leventhal, Elsa Bernard, et al.
The New England Journal of Medicine|April 23, 2025
Tumor-Infiltrating Clonal HematopoiesisOriol Pich, Elsa Bernard, Maria Zagorulya, et al.
Blood|April 30, 2024
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromesMaria Sirenko, Elsa Bernard, Maria Creignou, et al.
Blood|July 3, 2024
Molecular taxonomy of myelodysplastic syndromes and its clinical implicationsElsa Bernard, Robert P Hasserjian, Peter L Greenberg, et al.
Nature Genetics|October 27, 2020
Cancer therapy shapes the fitness landscape of clonal hematopoiesisKelly L Bolton, Ryan N Ptashkin, Teng Gao, et al.
NEJM Evidence|February 6, 2024
Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElsa Bernard, Heinz Tuechler, Peter L Greenberg, et al.
Nature Medicine|May 5, 2021
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesElsa Bernard, Yasuhito Nannya, Robert P Hasserjian, et al.
Pageof 6